Massey’s science-driven translational research – moving scientific discoveries from the laboratory into real-world patient applications – is one of the many reasons the National Cancer Institute recently awarded Massey a five-year renewal as one of only two NCI-designated Cancer Centers in Virginia. Often described as “bench-to-bedside” research, translational research involves several stages, including clinical trials, where consenting patients are given drugs, surgical procedures, devices or other interventions to treat cancer and are then closely monitored to determine side effects, effectiveness and other key findings.
Laboratory experiments conducted by scientists at Virginia Commonwealth University Massey Cancer Center suggest that a novel combination of the drugs ibrutinib and bortezomib could potentially be an effective new therapy for several forms of blood cancer, including diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL).
Scientists from Virginia Commonwealth University Massey Cancer Center and the VCU Institute of Molecular Medicine (VIMM) have provided evidence from preclinical experiments that a gene known as melanoma differentiation associated gene-9/syntenin (mda-9/syntenin) could be used as a therapeutic target to kill bladder cancer cells, help prevent metastasis and even be used to non-invasively diagnose the disease and monitor its progression. The study, published in the journal Clinical Cancer Research, was a collaborative effort between Paul B. Fisher, M.Ph., Ph.D., who originally discovered the mda-9/syntenin gene, and Santanu Dasgupta, Ph.D., an expert in bladder cancer research.
Electronic health records (EHRs) hold the promise to improve primary health care for millions of patients. However, enhancing current EHR functionality is needed to better support primary care clinicians and patients, according to a recent article.
Recently, the National Cancer Institute hosted a Twitter chat on cancer pain. Patrick Coyne, M.S.N., A.P.R.N., F.A.A.N., clinical director of the Palliative Care Program at VCU Massey Cancer Center and world-renowned pain management specialist, provided expert commentary as the moderator posed a series of questions and discussion topics.